CN1030890C - 一种药物组合物的制备方法 - Google Patents

一种药物组合物的制备方法 Download PDF

Info

Publication number
CN1030890C
CN1030890C CN91107596A CN91107596A CN1030890C CN 1030890 C CN1030890 C CN 1030890C CN 91107596 A CN91107596 A CN 91107596A CN 91107596 A CN91107596 A CN 91107596A CN 1030890 C CN1030890 C CN 1030890C
Authority
CN
China
Prior art keywords
solution
methyl
indole
ethyl
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN91107596A
Other languages
English (en)
Chinese (zh)
Other versions
CN1063099A (zh
Inventor
J·克雷格
D·L·克鲁克斯
S·J·施基特拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1063099A publication Critical patent/CN1063099A/zh
Application granted granted Critical
Publication of CN1030890C publication Critical patent/CN1030890C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CN91107596A 1990-12-12 1991-12-11 一种药物组合物的制备方法 Expired - Fee Related CN1030890C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments
GB9026998.6 1990-12-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN95100529A Division CN1050831C (zh) 1990-12-12 1995-02-20 取代的甲磺酰胺硫酸盐及其溶剂化物的制备方法

Publications (2)

Publication Number Publication Date
CN1063099A CN1063099A (zh) 1992-07-29
CN1030890C true CN1030890C (zh) 1996-02-07

Family

ID=10686904

Family Applications (2)

Application Number Title Priority Date Filing Date
CN91107596A Expired - Fee Related CN1030890C (zh) 1990-12-12 1991-12-11 一种药物组合物的制备方法
CN95100529A Expired - Fee Related CN1050831C (zh) 1990-12-12 1995-02-20 取代的甲磺酰胺硫酸盐及其溶剂化物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN95100529A Expired - Fee Related CN1050831C (zh) 1990-12-12 1995-02-20 取代的甲磺酰胺硫酸盐及其溶剂化物的制备方法

Country Status (36)

Country Link
US (2) US5554639A (cg-RX-API-DMAC7.html)
EP (1) EP0490689B1 (cg-RX-API-DMAC7.html)
JP (1) JP2994037B2 (cg-RX-API-DMAC7.html)
KR (1) KR100211479B1 (cg-RX-API-DMAC7.html)
CN (2) CN1030890C (cg-RX-API-DMAC7.html)
AP (1) AP230A (cg-RX-API-DMAC7.html)
AT (1) ATE119881T1 (cg-RX-API-DMAC7.html)
AU (1) AU650706B2 (cg-RX-API-DMAC7.html)
BE (1) BE1005085A3 (cg-RX-API-DMAC7.html)
CA (1) CA2098302C (cg-RX-API-DMAC7.html)
CH (1) CH684192A5 (cg-RX-API-DMAC7.html)
CY (1) CY2005A (cg-RX-API-DMAC7.html)
CZ (1) CZ281931B6 (cg-RX-API-DMAC7.html)
DE (1) DE69108200T2 (cg-RX-API-DMAC7.html)
DK (1) DK0490689T3 (cg-RX-API-DMAC7.html)
EG (1) EG20219A (cg-RX-API-DMAC7.html)
ES (1) ES2069836T3 (cg-RX-API-DMAC7.html)
FR (1) FR2670487B1 (cg-RX-API-DMAC7.html)
GB (2) GB9026998D0 (cg-RX-API-DMAC7.html)
GR (1) GR3015430T3 (cg-RX-API-DMAC7.html)
HK (1) HK82697A (cg-RX-API-DMAC7.html)
HU (1) HU211937A9 (cg-RX-API-DMAC7.html)
IE (1) IE62894B1 (cg-RX-API-DMAC7.html)
IL (1) IL100330A (cg-RX-API-DMAC7.html)
IS (1) IS1706B (cg-RX-API-DMAC7.html)
IT (1) IT1252868B (cg-RX-API-DMAC7.html)
MX (1) MX9102501A (cg-RX-API-DMAC7.html)
MY (1) MY109265A (cg-RX-API-DMAC7.html)
NL (1) NL9102071A (cg-RX-API-DMAC7.html)
NZ (1) NZ240942A (cg-RX-API-DMAC7.html)
PT (1) PT99757B (cg-RX-API-DMAC7.html)
RU (1) RU2108328C1 (cg-RX-API-DMAC7.html)
TW (2) TW205035B (cg-RX-API-DMAC7.html)
WO (1) WO1992010477A1 (cg-RX-API-DMAC7.html)
YU (1) YU48926B (cg-RX-API-DMAC7.html)
ZA (1) ZA919750B (cg-RX-API-DMAC7.html)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279211B6 (sk) * 1992-06-05 1998-08-05 Merck Sharp & Dohme Limited Sulfátová soľ substituovaného triazolu, spôsob jej
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US20050269402A1 (en) * 2004-06-03 2005-12-08 Tyfone, Inc. System and method for securing financial transactions
WO2005123043A2 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
CA2609185A1 (en) 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
JP2010522135A (ja) 2006-10-09 2010-07-01 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
CN101687788A (zh) * 2006-10-19 2010-03-31 奥斯拜客斯制药有限公司 取代的吲哚
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
AU2009253738B2 (en) 2008-05-27 2012-12-13 Biota Scientific Management Pty Ltd Antiviral salts
AU2009260166B2 (en) * 2008-06-20 2014-10-09 Alphapharm Pty Ltd Pharmaceutical formulation
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
EP2296652B1 (en) * 2008-06-30 2017-11-08 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US9211282B2 (en) * 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
JP2018507262A (ja) 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
JP6897971B2 (ja) 2015-05-15 2021-07-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 関節炎を処置するための、方法および組成物
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
KR20250035619A (ko) 2017-11-07 2025-03-12 더 리젠츠 오브 더 유니버시티 오브 미시건 공유 에피토프-칼레티쿨린 상호 작용의 소분자 억제제 및 사용 방법
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
US20230108049A1 (en) * 2020-02-27 2023-04-06 Biohaven Pharmaceutical Holding Company Ltd. Oral fast-dispersing dosage form of rimegepant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
BE1005085A3 (fr) 1993-04-13
IE62894B1 (en) 1995-03-08
CA2098302A1 (en) 1992-06-13
FR2670487A1 (fr) 1992-06-19
AP9100339A0 (en) 1992-01-31
IE914317A1 (en) 1992-06-17
IL100330A (en) 1996-06-18
TW300886B (cg-RX-API-DMAC7.html) 1997-03-21
PT99757A (pt) 1992-12-31
GB9026998D0 (en) 1991-01-30
AU650706B2 (en) 1994-06-30
ZA919750B (en) 1992-10-28
ITRM910922A0 (it) 1991-12-11
GR3015430T3 (en) 1995-06-30
CN1063099A (zh) 1992-07-29
JPH06503560A (ja) 1994-04-21
JP2994037B2 (ja) 1999-12-27
MX9102501A (es) 1992-09-01
MY109265A (en) 1996-12-31
DE69108200D1 (de) 1995-04-20
GB2251614A (en) 1992-07-15
CN1050831C (zh) 2000-03-29
TW205035B (cg-RX-API-DMAC7.html) 1993-05-01
EP0490689B1 (en) 1995-03-15
IS3790A7 (is) 1992-06-13
HU211937A9 (en) 1996-01-29
DK0490689T3 (da) 1995-05-22
NL9102071A (nl) 1992-07-01
AP230A (en) 1993-01-27
CY2005A (en) 1997-12-05
HK82697A (en) 1997-06-27
IL100330A0 (en) 1992-09-06
US5554639A (en) 1996-09-10
EP0490689A1 (en) 1992-06-17
CZ281931B6 (cs) 1997-04-16
US5705520A (en) 1998-01-06
ES2069836T3 (es) 1995-05-16
YU191491A (sh) 1994-04-05
CH684192A5 (fr) 1994-07-29
WO1992010477A1 (en) 1992-06-25
RU2108328C1 (ru) 1998-04-10
GB9126297D0 (en) 1992-02-12
IT1252868B (it) 1995-06-28
AU9072091A (en) 1992-07-08
ITRM910922A1 (it) 1993-06-11
YU48926B (sh) 2002-12-10
FR2670487B1 (fr) 1993-08-20
CN1128259A (zh) 1996-08-07
GB2251614B (en) 1994-12-14
CZ114093A3 (en) 1994-02-16
NZ240942A (en) 1994-03-25
CA2098302C (en) 2001-10-16
DE69108200T2 (de) 1995-07-20
PT99757B (pt) 1999-05-31
EG20219A (en) 1997-11-30
IS1706B (is) 1998-12-10
ATE119881T1 (de) 1995-04-15
KR100211479B1 (ko) 1999-08-02

Similar Documents

Publication Publication Date Title
CN1030890C (zh) 一种药物组合物的制备方法
US12090139B2 (en) Formulations comprising triptan compounds
US5393773A (en) Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
CN100423709C (zh) 包括芬太尼的鼻内递送用药物组合物
RU2130022C1 (ru) N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство
US11337962B2 (en) Formulations comprising triptan compounds
CN102933198B (zh) 包含曲普坦化合物的制剂
RU2710372C2 (ru) Композиции, содержащие триптановые соединения
NO179102B (no) 3-[2-(dimetylamino)etylÅ-N-metyl-1H-indol-5-metansulfonamid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 19960207

Termination date: 20100111